Blog: Patient Insights & Thought Leadership

Healthcare Industry Thought Leadership

Health Union’s data-driven industry conversations help pharma make smarter, more effective decisions.
Check out our latest thought leadership pieces below.

Lung Cancer Patient-Reported Survey Data | 2020

August 13, 2020

Many people living with lung cancer report feeling a stigma associated with their condition, according to new Health Union survey data.

Patients play an active role in their treatment

Playing an Active Role in Treatment Yields More Confidence in Patients

August 4, 2020

Whether a person plays an active role in treatment or not, the majority of patients surveyed do not feel controlled on their current treatment plan.

Steroid Withdrawal Concerns in People with Atopic Dermatitis

July 30, 2020

More than half of people living with atopic dermatitis who have ever used topical corticosteroids say they are at least “somewhat concerned” about steroid withdrawal.

Psoriatic Arthritis Patient-Reported Data | 2020

July 29, 2020

Only 12% of people living with psoriatic arthritis feel satisfied on their current treatment plan, according to new Health Union survey data.

Let’s Talk About Sex: Why Treating Intimacy As a Clinical Symptom Matters

February 5, 2021

Findings from Health Union’s In America surveys show sex and intimacy can be greatly impacted by a person’s condition, including symptoms and side effects.

The Year of Substance: Finding Success During 2020 and Beyond

January 22, 2021

For Health Union in 2020, substance can be attributed to our mission and core values, a strong people-first culture and the ability to adapt.

5 Ways to Make Your Pharma Marketing More Personal

January 20, 2021

Break through the noise and reach and engage people during their unique health journey with our tips to help personalize your pharma marketing strategies.

The Positive Impact of CFTR Modulators: a Year-Over-Year Comparison

December 22, 2020

Current CFTR modulator usage increased from nearly half of respondents in 2019, when three modulators were approved, to 68% in 2020.

Healthcare Industry Thought Leadership

Contact